Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High intensity focused ultrasound (HIFU) and Eligard in patients with high risk prostate cancer - HELP

Next Previous
X
Search
Trial Profile

High intensity focused ultrasound (HIFU) and Eligard in patients with high risk prostate cancer - HELP

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms HELP

    • Most Recent Events

    • 21 Mar 2023 Results published in the EDAP media release.
    • 21 Mar 2023 According to EDAP media release, company announced presentation of positive results from this study at the 38th Annual Congress of the European Association of Urology (EAU), which was held from 10th-13th March 2023 in Milan, Italy.
    • 15 Dec 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top